Featured News
LuGENE® Lupus Test Launches to Predict Flares & Drug Targets
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
Virginia Workforce Award to AMPEL BioSolutions
AMPEL on Bloomberg Markets
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Innovator-of-Year to AMPEL
Lupus
Monitoring Lupus with Data: a discussion with Dr. Schneider(Stanford) & Dr. Grammer (AMPEL’s LuGENE Flare Blood Test)
LuGENE® Lupus Test Launches to Predict Flares & Drug Targets
AMPEL BioSolutions announces a breakthrough in personalized precision medicine that will revolutionize the way doctors manage the autoimmune disease Lupus. Revealed in the peer-reviewed journal Genome Medicine and being made available to patients through a US follow-on study, the LuGENE® blood test forecasts patient flares and drug targets from gene expression utilizing predictive AI.
New Blood Test Poised to Revolutionize Care for Systemic Lupus Erythematosus
AMPEL BioSolutions announced the launch of LuGENE®, an exciting breakthrough innovation in systematic lupus erythematosus (SLE) care. LuGENE® is a new blood test designed to predict SLE flares before they happen and provide specific information about each individual’s disease abnormalities, leading to faster, evidence-based treatment.
Dermatology
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
After nine years in business, precision medicine company AMPEL BioSolutions is broadening its market from pharmaceutical companies to healthcare providers and their patients.
AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Drug Options for Inflammatory Skin Diseases
AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat inflammatory skin diseases, such as Lupus, Psoriasis, Atopic Dermatitis and Scleroderma.
Ready for Prime Time? Ampel’s Blood Tests May Predict Drug Options for Inflammatory Skin Disease
Products expected to launch in 2022-2023 include LuGENE, a blood test for Lupus, and DermaGENE a skin biopsy test for lupus, psoriasis, atopic dermatitis, and scleroderma.
Wellness
Transforming Digital Health with Genomic Data and AI
In this seminar we will explore the cutting-edge intersection of AI and genomics that is reshaping the landscape of healthcare.
AMPEL BioSolutions Selected as Member of Prestigious Federal Health Innovation ARPA-H Network
AMPEL BioSolutions has been selected as a member – or “spoke” – of the Customer Experience Hub of ARPANET-H, a prestigious nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
Today AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients.
Nephrology
AMPEL BioSolutions Developing Molecular Test to Predict Kidney Damage in Lupus Nephritis Patients
According to the company, the test identifies molecular markers in kidney biopsy samples of LN patients, which can help reveal patients’ disease stage. This information, in turn, could help those pharmaceutical companies who have more than 45 LN drugs in development enroll patients in clinical trials with greater precision, AMPEL said.
New test to identify, treat kidney disease
CLICK TO READ ARTICLE & VIEW VIDEO > By Felicity Taylor CHARLOTTESVILLE, Va. (CBS19 NEWS) -- A local company says it has discovered a new way to identify and treat kidney disease. AMPEL BioSolutions is a precision medicine company that studies RNA and gene...
AMPEL BioSolutions’ Breakthrough Predicts Drug Options to Slow End Stage Renal Disease
CLICK TO VIEW ARTICLE > CHARLOTTESVILLE, Va., March 1, 2023 /PRNewswire/ -- AMPEL BioSolutions today announced a genomic precision medicine test for chronic kidney diseases, such as Lupus Nephritis, that could save lives by predicting kidney damage before it is...
Cardiology
AMPEL develops a blood test for cardiovascular disease
Armie Grammer, AMPEL’s co-founder, president, and chief scientific officer of AMPEL BioSolutions, explains the company’s CardioGENE blood test for cardiovascular disease risk.
New Blood Test Can Predict Heart Disease and Guide Prophylactic Treatment
AMPEL BioSolutions’ new CardioGENE blood test predicts heart disease by identifying genetic markers and inflammatory pathways, enabling personalized, preventive therapies.
Precision Medicine Blood Test Predicts Heart Disease Before It Occurs
A precision medicine blood test can predict heart disease before it happens and provide decision support for prophylactic therapies.
Fibromyalgia
AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia
Paired with AMPEL’s pipeline of tools to analyze very large and complex clinical datasets (“Big Data”), FibroGENE® is a significant step towards implementing a routine test for monitoring fibromyalgia and providing decision support for treatment based on a patient’s gene expression. This will transform the way doctors treat fibromyalgia by using the information gathered by the lab test and analyzed by bioinformatics to characterize the precise molecular abnormalities and treat symptoms, reduce pain and increase the quality of life of millions of Americans.
Experimental Blood Test Could Improve Fibromyalgia Treatment
A small pilot study suggests an experimental blood test for fibromyalgia – called FibroGENE — could be used to determine which drug works best for each patient. Researchers at AMPEL BioSolutions and Duke University Medical Center found genetic biomarkers in the blood cells of 18 lupus patients with fibromyalgia-like symptoms.
Local company unveils blood test to find treatments for chronic pain
A medical discovery has been made in Charlottesville that may help people who experience chronic pain, fatigue and brain fog. “This is a big problem. This is a clinical problem that is not addressed. And it’s a problem that tends to discount patients,” said CEO and Chief Medical Officer Peter Lipsky.
Infections
Genomic tests help doctors treat COVID-19 and long COVID
With many COVID-19 treatments now available, a simple blood test can show doctors the best route to take. Charlottesville’s AMPEL BioSolutions says it can predict and detect the severity of a COVID-19 infection, as well as how to help a patient through its new genomic test called CovGENE.
AMPEL’s CovGENE blood test predicts COVID19 severity and holds promise for long COVID
AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that can detect and predict the severity of COVID-19 in patients while also determining the best treatment options for each specific case.
New test shows whether someone infected with COVID will develop a bad case
While the COVID pandemic is easing in some places, the CDC says it’s the third leading cause of death for the third year in a row. Now, a Virginia company says it’s got a test that will help doctors determine which patients are at greatest risk so they can prescribe the best treatment.